liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder A randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents
Eli Lilly Sweden AB.
Lund University.
Linköping University, Department of Clinical and Experimental Medicine, Child and Adolescent Psychiatry . Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Local Health Care Services in Central Östergötland, Department of Child and Adolescent Psychiatry.
Umeå University.
Show others and affiliations
2009 (English)In: EUROPEAN CHILD and ADOLESCENT PSYCHIATRY, ISSN 1018-8827, Vol. 18, no 4, 240-249 p.Article in journal (Refereed) Published
Abstract [en]

Objective The primary objective of this study was to assess the impact of atomoxetine in combination with psychoeducation, compared with placebo and psychoeducation, on health-related quality of life (HRQL) in Swedish stimulant-naive pediatric patients with attention deficit/hyperactivity disorder (ADHD). HRQL results will be presented elsewhere. Here, psychoeducation as well as efficacy and safety of the treatment are described. Patients and methods A total of 99 pediatric ADHD patients were randomized to a 10-week double-blind treatment with atomoxetine (49 patients) or placebo (50 patients). Parents of all patients received four sessions of psychoeducation. Atomoxetine was dosed up to approximately 1.2 mg/kg day (<= 70 kg) or 80 mg/day (>70 kg). Improvement of ADHD symptoms was evaluated using the ADHD rating scale (ADHD-RS) and clinical global impression (CGI) rating scales. Safety was assessed based on adverse events (AEs). Results The study population was predominantly male (80.8%) and diagnosed with the combined ADHD subtype (77.8%). The least square mean (lsmean) change from baseline to endpoint in total ADHD-RS score was -19.0 for atomoxetine patients and -6.3 for placebo patients, resulting in an effect size (ES) of 1.3 at endpoint. Treatment response (reduction in ADHD-RS score of >= 25 or >= 40%) was achieved in 71.4 or 63.3% of atomoxetine patients and 28.6 or 14.3% of placebo patients. The lsmean change from baseline to endpoint in CGI-Severity group compared with -0.3 in the placebo group. The difference between treatments in CGI-Improvement at endpoint was -1.4 in favor of atomoxetine. No serious AEs occurred. The safety profile of atomoxetine was in line with the current label. Conclusions Atomoxetine combined with psychoeducation was superior to placebo and psychoeducation in ADHD core symptoms improvement. The large ES might be a result of including stimulant-naive patients only, but also may indicate a positive interaction between atomoxetine treatment and psychoeducation, possibly by increased compliance.

Place, publisher, year, edition, pages
2009. Vol. 18, no 4, 240-249 p.
Keyword [en]
ADHD, atomoxetine, clinical research/trial, parenting education, pharmacotherapy
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-17898DOI: 10.1007/s00787-008-0725-5OAI: diva2:212986
Available from: 2009-04-26 Created: 2009-04-24 Last updated: 2009-08-21

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Gustafsson, Per
By organisation
Child and Adolescent Psychiatry Faculty of Health SciencesDepartment of Child and Adolescent Psychiatry
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 53 hits
ReferencesLink to record
Permanent link

Direct link